GlassScriptPhysician profile
Jasmine Joseph
NPI 1205397635
$7,207.91
in general payments reported to CMS, 2019-2025
48 companies · $2,813 in 2025
The $2,813 reported for 2025 was more than what 96% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $449 · 2022: $711 · 2023: $1,226 · 2024: $2,009 · 2025: $2,813.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,048.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,048.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,261.90 | 2022-2025 | |
| Novartis Pharmaceuticals Corporation | $764.61 | 2022-2025 | |
| Teva Pharmaceuticals USA, INC. | $700.23 | 2022-2025 | Ajovy, Austedo Xr, Austedo Xr |
| Lilly USA, LLC | $699.07 | 2021-2025 | Kisunla, Emgality, Amyvid |
| Pfizer INC. | $410.38 | 2021-2025 | |
| Biogen, INC. | $285.03 | 2022-2025 | Vumerity, Spinraza, Tysabri |
| Argenx US, INC. | $267.23 | 2022-2025 | Vyvgart, Vyvgart Hytrulo |
| Eisai INC. | $256.76 | 2022-2025 | |
| Alnylam Pharmaceuticals INC. | $231.34 | 2024-2025 | Amvuttra, Onpattro |
| Astrazeneca Pharmaceuticals LP | $208.32 | 2021-2025 | Wainua |
| Neurocrine Biosciences, INC. | $198.68 | 2023-2025 | Ingrezza, Ongentys |
| Glaxosmithkline, LLC. | $194.36 | 2021 | |
| Impel Pharmaceuticals INC. | $191.53 | 2022-2023 | Trudhesa |
| Lundbeck LLC | $187.52 | 2022-2025 | Rexulti, Vyepti |
| Ucb, INC. | $158.25 | 2022-2025 | Fintepla, Rystiggo, Nayzilam |
Show all 48 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jasmine Joseph listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.